The European Joint Action on Personalised Cancer Medicine officially launched on January 14, bringing together 29 European countries and over 140 partner organisations to advance personalised cancer care across Europe. Coordinated by the Belgian public health institute Sciensano, the project aims to create a sustainable cross-border network to foster innovation, equity, and collaboration in personalised cancer prevention, diagnosis, treatment, follow-up and tertiary prevention.
Oslo University Hospital (OUS) serves as the Norwegian coordinator. 

"RNA Therapeutics: From siRNA to mRNA Innovations", edited by Mouldy Sioud and published by Springer Nature, presents a comprehensive and authoritative overview of the scientific advances driving the rapid growth of RNA-based therapeutics. This landmark volume brings together leading international experts to explore the evolution of RNA technologies and their expanding role in modern medicine.
Mouldy Sioud leads the Immunomodulation and Targeted Therapies research group at the Department of Cancer Immunology at the Institute for Cancer Research.

Recommended sites for current OUS research news:

From Oslo University Hospital, in Norwegian:
OUS Innsikt – ny forskning, innovasjon og behandling - channel for science communication
More news from OUS (oslo-universitetssykehus.no)

From centres of excellence (UiO/OUS):
CanCell - Centre for Cancer Cell Reprogramming 
Cresco - Centre for Embryology and Healthy Development 
PRIMA - Precision Immunotherapy Alliance - Norwegian version
Hybrid Technology Hub - Centre for Organ on a Chip-Technology

Oslo University Hospital hereby announce research awards in the following two catagories for 2026:

• Excellent Researcher Award (one prize, 400.000 NOK)
• Early Career Award (two prizes of 200.000 NOK each)

Closing date for nominations: March 2nd 2026.

Emma Lång, member of the "Cell and tissue dynamics research group" at the Department of Microbiology, has received 9 million NOK in funding from Helse Sør-Øst RHF for her project "Navigating the Tunnel: Keratinocyte Dynamics & Therapeutic Targeting of IL-17 in Hidradenitis Suppurativa".

This interdisciplinary study aims to uncover the underlying cellular mechanisms of the chronic inflammatory skin disease, Hidradenitis Suppurativa (HS). HS is a debilitating disease that severely impacts patients’ quality of life, with current treatments being insufficient and late diagnosis complicating care.

Lorena Arranz, leader of the Stem Cells, Ageing and Cancer research group at the Department of Microbiology and Deputy Centre Director of CRESCO, has received 9 million NOK in funding from Helse Sør-Øst RHF for her project NEUROTARGET: The nervous system as a druggable vulnerability in myeloid blood cancers.

Helse Sør-Øst RHF has awarded regional research funding to 96 research projects starting in 2026. The projects cover a wide range of disciplines and aim to contribute new knowledge and improved patient care. Lorena Arranz received funding from the thematic open structure, available to all research areas in the specialist healthcare services.

Before the Christmas break, the major Norwegian TV channel TV2 visited the Radium Hospital to learn about the Pseudovax trial. The first patient that recived the vaccine, Mette, was the main focus, together with comments from general secretary Ingrid Stenstadvold Ross in the Norwegian Cancer Society and Kjersti Flatmark, one of the lead investigators of the study. 
The Pseudovax clinical trial will evaluate a novel cancer vaccine developed at the Norwegian Radium Hospital specifically for patients with Pseudomyxoma peritonei (PMP) . 
"If the vaccine proves to be effective, we hope that this could become an new treatment option for patients with PMP who are not cured by surgery", Flatmark says.

The Royal Society in England has awarded a prestigious research grant to support pioneering work on focused ultrasound–based therapy for brain diseases, led by Dr. Mohammad Zoofaghari. He is a member of the Wireless Sensor Network Research Group, headed by Prof. Ilangko Balasingham at The Intervention Centre, Division of Technology and Innovation.
The project aims to revolutionize how focused ultrasound treatments are delivered, particularly when multiple brain regions require simultaneous treatment. Current methods often struggle because different brain regions and skull variations respond differently to ultrasound waves, leading to uneven treatment and reduced effectiveness.

A research team led by Arne Søraas at Oslo University Hospital is competing for more than one billion NOK in an international XPRIZE contest to demonstrate that treatment with young blood plasma can slow the aging processes. The project’s primary aim is to investigate whether plasma from young donors can stabilize or reduce cognitive decline in patients with early Alzheimer’s disease. The idea may sound like science fiction, but it builds on longstanding animal experiments in which socalled parabiosis showed that blood from young animals can produce measurable improvements in the brain function of older animals.

Webmaster www.ous-research.no:

Trond Olav Berg